Grifols SA
MAD:GRF
Decide at what price you'd be comfortable buying and we'll help you stay ready.
Intrinsic Value
The intrinsic value of 
Grifols SA (GRF) under the Base Case is 15.1 EUR per share.
Compared with the current market price of 11.65 EUR, the stock appears
Undervalued by 23% .
The intrinsic value is calculated using the DCF method. The model assumes operating margin rises from 17% last year to 22% by 2031, higher than in any of the last six years. If operating margin stayed at its five-year average of 13%, the estimate would be about €2.72.
Do our valuations actually work? See backtest results .
Cheap or expensive for this stock?
This block shows whether today’s valuation is cheap or expensive compared with the stock’s own history, and what happened after similar valuations in the past.
We compare the gap between the stock’s price and our estimated value over time.
- Undervalued can still be historically expensive. The stock may trade below our estimated value, but usually offer an even bigger discount.
- Overvalued can still be historically cheap. The stock may trade above our estimated value, but usually carry an even higher premium.
Market expectations can differ from our model, which may not fully capture everything affecting the price. That is why some stocks regularly trade above our estimated value and others below it.
The scale and chart show how today’s valuation compares with the past. The cards summarize past returns and waiting times until the stock stopped being cheap or expensive. This can happen because the price changed, our estimated value changed, or both.
Only completed periods are included. These are past results, not forecasts. The usual historical range does not necessarily mean fair value.
Fundamental Analysis
What Grifols Does
Grifols is a healthcare company that makes medicines and diagnostic products from human plasma. Its main products are plasma-derived therapies used to treat immune disorders, bleeding conditions, and other serious illnesses, along with diagnostic test systems and blood-typing tools used in labs and hospitals. It also runs plasma collection centers, which supply the raw material for its medicines.
- Headquarters
- Spain ES
- Employees
- 25 000
- IPO date
- May 17, 2006
Grifols has no economic moat
Grifols SA lacks an economic moat, leaving it vulnerable to competitive pressures and market challenges.
Read the full moat analysis
Revenue & Expenses Breakdown
Grifols SA
Earnings Waterfall
Grifols SA
What is the Intrinsic Value of one GRF stock?
The intrinsic value for Grifols SA (GRF) under the Base Case is 15.1 EUR.
Is GRF stock undervalued or overvalued?
Compared with the current market price of 11.65 EUR, the stock appears Undervalued by 23% .
